摘要
Objective: To further evaluate the clinical usefulness of ondensetron(OND, supplied by Qilu Pharmaceutical Company) with modified regime in the prevention of cisplatin (DDP)-induced nausea and vomiting. Methods: A total of 773 patients were enrolled in a multicenter cooperative study. Of them, 330 patients were given iv OND 8 mg once or twice a day and 443 patients were given iv OND 8 mg plus dexamethasone(DXM) 10 mg once a day during the therapeutic period of DDP, followed by OND 4 mg orally twice a day for two days after DDP treatment. Results: Effective control of acute nausea was achieved in 86.7% and 94.8% of the patients receiving OND alone and OND plus DXM, respectively (P<0.001). The mean frequency of vomiting was 0.9 times in OND and 0.4 times in OND plus DXM (P<0.01). Total control of delayed vomiting (day 2~5) was comparable in both groups. Complete inhibition of vomiting (CR rate) was more frequently observed in males than in females. Adverse effects were identical and well tolerated. Conclusion: OND with modified regimen is effective in the control of DDP-induced vomiting. It is more effective when OND and DXM are given than OND given alone.
| 源语言 | 英语 |
|---|---|
| 页(从-至) | 358-361 |
| 页数 | 4 |
| 期刊 | Zhonghua zhong liu za zhi [Chinese journal of oncology] |
| 卷 | 19 |
| 期 | 5 |
| 出版状态 | 已出版 - 1997 |
学术指纹
探究 'Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by cisplatin' 的科研主题。它们共同构成独一无二的学术指纹。引用此
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver